Patients Tired of Toxic Chemotherapies Current data shows efficacy & amp; maintaining quality of life
Jon Eckard, PhD, TYME Inc., explains Patients Tired of Toxic Chemotherapies Current data shows efficacy & maintaining quality of life at ASCO 2018.
Author: Annual-Meeting
Added: 06/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolong...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Selenium for preventing cancer
More than half a dozen Cochrane Reviews have been done in various areas of health, to examine the evidence on the potential benefits of Selenium, a naturally occurring element with both nutritional and toxicological properties. The review looking at its possible role in the prevention of cancer was updated in January 2018 and one of the authors, Maree Brinkman from the Nutrition Biomed Research Institute in Melbourne in Australia. gives us the latest findings in this podcast. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - May 25, 2018 Category: General Medicine Authors: Cochrane Source Type: podcasts
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolong...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Selenium for preventing cancer
More than half a dozen Cochrane Reviews have been done in various areas of health, to examine the evidence on the potential benefits of Selenium, a naturally occurring element with both nutritional and toxicological properties. The review looking at its possible role in the prevention of cancer was updated in January 2018 and one of the authors, Maree Brinkman from the Nutrition Biomed Research Institute in Melbourne in Australia. gives us the latest findings in this podcast. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - May 25, 2018 Category: General Medicine Authors: Cochrane Source Type: podcasts
Are There Clinically Significant Distinctions Between PD-1 and PD-L1_ [720p]
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Author: cancergrace
Added: 05/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities
Ruben Niesvizky, MD, explains Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities
Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Professional education and training on the management CAR T-cell toxicities
CAR T-cell agents, as a breakthrough therapy, have their challenges. Here, Rose Ellard from Kings College Hospital NHS Foundation Trust, London, UK, outlines the importance of formal training in mana...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advance...
Author: BeaconMedIC
Added: 04/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because of toxicity
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because...
Author: Cancer-News
Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Rucaparib, Niraparib, and Olaparib all Show Benefit Differences between the drugs, are in their toxicities
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences between the drugs, are in their toxiciti...
Author: Cancer-News
Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts
How do you indentify a toxicity being related to the axitnib or the pembrolizumab?
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers How do you indentify a toxicity being related to the axitnib or the pembrol...
Author: Cancer-News
Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy Can have Activity in the Brain Do better at managing toxicities
Santosh Kesari, MD, discusses how Immunotherapy Can have Activity in the Brain Do better at managing toxicities at the 2018 Oncology Summit in Huntington Beach, CA <br /><br />Go to: <a target='_blank' href='http://www.moasc.org'>http://www.moasc.org...</a> fo...
Author: moasc
Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Is Genotype Screening Needed Before Fluoropyrimidines?
Dr David Kerr on how the recent case for DPYD screening may be on (and off) mark in addressing chemotherapy toxicity. (Source: Medscape Oncology)
Source: Medscape Oncology - March 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
